ADM Diagnostics (ADMdx)

07/12/2024

Our work regarding "Relationships between plasma biomarkers, Tau PET, FDG PET, and volumetric MRI in Mild to Moderate Alzheimer’s disease patients” has been published in Alzheimer's & Dementia: Translational Research & Clinical Interventions. This study, led by Dr. Jeffrey Cummings and Dr. Jefferson Kinney, with analysis by ADMdx, demonstrated correspondence between blood tests and imaging, the complimentary insight they provide to patient status, and the effects of covariates such as age.

Alzheimer's & Dementia: Translational Research & Clinical Interventions journal bridges drug discovery research and clinical studies for dementia & Alzheimer's.

10/27/2023

Honored to speak on the Biomarker panel at the Alzheimer's Drug Discovery Foundation Therapeutic Investigator Day. This symposium, along with the Clinical Trials in Alzheimer's Disease conference that followed, included an unprecedented set of encouraging research outcomes toward the effective treatment of Alzheimer's Disease.

09/18/2023

Recent research further supports the association between exercise (i.e. avoiding a sedentary lifestyle, such as sitting for 12 hours a day) and reduced risk of dementia. This study provided a possible biochemical mechanism behind the connection.

Sit Less, Move More to Induce Irisin and Stave Off Dementia Quick Links Article Comments References Further Reading Tools Add to my Library Follow Comments Share How would you like to share? Facebook Twitter LinkedIn Back to the Top 14 Sep 2023 Physical activity staves off dementia, but does that me...

05/03/2023

Our work was recently published in collaboration with Enigma/Cerveau (Lantheus) in the validation of a visual reading method for a new tau PET radiotracer, MK-6240. As part of this work, ADMdx read 1,842 tau PET scans and evaluated associations with amyloid and clinical status. Results were very well aligned with tau findings from neuropathology studies. The ability to "see" and measure tau in the brain in vivo is a powerful tool contributing to research, diagnosis, and ultimately treatment.

Background The positron emission tomography (PET) radiotracer [18F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity t...

05/03/2023

Exciting news in Alzheimer's disease -- Lilly's anti-amyloid drug Donanemab has successfully met all of its Phase III pivotal clinical trial endpoints, slowing cognitive and functional decline in patients. This drug had been successful in its Phase II trial, but drugs often do not succeed in their larger Phase III trials. Donanemab removes an abnormal protein called amyloid in the brain, and in Phase II studies also showed a reduction of abnormal tau protein - - together, those two abnormal proteins (amyloid plaques and neurofibrillary tau tangles) constitute a diagnosis of Alzheimer's disease. This will be the third drug to be approved by the FDA (expected) as a disease-modifying therapeutic for Alzheimer's disease, and it is the first to actually meet all of its endpoints. There is still progress to be made in preventing and treating AD but this is a significant step and brings hope for patients with AD.

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

07/29/2022

Our work using machine learning and early frame amyloid PET to characterize neuronal function and predict cognitive decline was recently published in Alzheimer’s&DemTRCI: https://lnkd.in/g8JGmnww

Introduction Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early-stage subjects do not worsen cl...

07/29/2022

Honored to be participating authors in the newly released book Alzheimer's Disease Drug Development - Research and Development Ecosystem, Edited by J Cummings, J Kinney, H Fillit: https://lnkd.in/g7bM9aXw

Cambridge Core - Neurology and Clinical Neuroscience - Alzheimer's Disease Drug Development

12/14/2021

ADM Diagnostics, Inc. Announces Launch of CorInsights® MRI

CorInsights MRI Provides Exceptional Insight Using Brain Volume Quantitation

06/28/2021

https://www.auntminnie.com/index.aspx?sec=sup&sub=mol&pag=dis&ItemID=132773

When it comes to imaging diseases like COVID-19, FDG-PET/CT may not be the first modality that springs to mind. But its performance over the past year for identifying infection and inflammation in COVID-19 patients offers strong evidence of its value.

06/24/2021

Lilly has been awarded a Breakthrough Therapy Designation in their FDA drug application for donanemab, a potential Alzheimer's therapy that had positive clinical trial results as described in the following release from earlier this year https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-slows-clinical-decline-alzheimers-disease

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

06/24/2021

Underdiagnosis remains prevalent for Alzheimer's disease... https://medicalxpress.com/news/2021-06-seniors-undiagnosed-dementia-previously-thought.html

Only 1 in 10 older adults in a large national survey who were found to have cognitive impairment consistent with dementia reported a formal medical diagnosis of the condition.

06/19/2021

The results of our collaborative work in the study of rasagiline for treatment of patients with Alzheimer's Disease have been published in Alzheimer's & Dementia: Translational Research and Clinical Intervention. In this study, led by Dr. Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health and sponsored by the Alzheimer's Drug Discovery Foundation, patients treated with rasagiline showed less decline in glucose metabolism (measured with FDG PET) in frontostriatal networks than placebo-treated patients. Clinical endpoints showed directional benefit, particularly Quality of Life. Link: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.12106

Background A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO-B) inhibitor approved for Parkinson disease, in...